Source:http://linkedlifedata.com/resource/pubmed/id/19070734
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9655
|
pubmed:dateCreated |
2008-12-16
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1474-547X
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
13
|
pubmed:volume |
372
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2020; author reply 2020-1
|
pubmed:meshHeading |
pubmed-meshheading:19070734-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:19070734-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:19070734-Drug Therapy, Combination,
pubmed-meshheading:19070734-Endpoint Determination,
pubmed-meshheading:19070734-Humans,
pubmed-meshheading:19070734-Randomized Controlled Trials as Topic
|
pubmed:year |
2008
|
pubmed:articleTitle |
Renal outcomes in the ONTARGET study.
|
pubmed:publicationType |
Letter,
Comment
|